📄 JAGUAR HEALTH, INC.

Jaguar Health is a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products. Its subsidiary Napo Pharmaceuticals commercializes Mytesi (crofelemer), an FDA-approved anti-secretory agent for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company is also developing follow-on indications for crofelemer and a second-generation anti-secretory agent, lechlemer. Key risk: The sale of our common stock to Oasis Capital may cause substantial dilution to our existing stockholders and the sale of the shares of common stock acquired by Oasis Capital could cause the price of our common stock to decline. Proceeds: Working capital and general corporate purposes, Additional purchase of API and drug product to address potential impact of coronavirus pandemic

Jaguar Health is a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products. Its subsidiary Napo Pharmaceuticals commercializes Mytesi (crofelemer), an FDA-approved anti-secretory agent for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company is also developing follow-on indications for crofelemer and a second-generation anti-secretory agent, lechlemer.